Cholesterol Enzyme DHCR24 Emerges as Driver and Biomarker of Endometrial Cancer

Endometrial carcinoma, one of the most common gynecological malignancies in the developed world, has been quietly changing its demographic profile. Once considered primarily a disease of postmenopausal women, its incidence has been climbing steadily, particularly among younger and obese women, mirroring the global rise in obesity-related metabolic dysfunction. While early-stage disease is usually curable with surgery, advanced and recurrent endometrial cancer remains stubbornly difficult to treat, and clinicians have long called for biomarkers that can reliably flag patients at risk of aggressive disease. Now, a new study published in Medical Oncology points to an unexpected culprit hiding in plain sight within one of the body’s most basic biochemical assembly lines: the cholesterol synthesis pathway.

A team of researchers led by Fei Li, Yuanyuan Wang, and senior author Xiuwei Chen of the Department of Gynecology at Harbin Medical University Cancer Hospital in China has identified DHCR24, the terminal enzyme of cholesterol biosynthesis, as a potent promoter of endometrial carcinoma progression and a candidate prognostic marker. The enzyme, formally known as 24-dehydrocholesterol reductase, catalyzes the final step of cholesterol production by converting the sterol intermediate desmosterol into cholesterol. Beyond its metabolic day job, however, DHCR24 has increasingly been implicated in cancer biology, with prior reports linking it to breast cancer stem-like cells, bladder cancer metastasis, and chemotherapy resistance in ovarian cancer. What remained unclear was its precise clinical relevance and biological role in tumors of the endometrium.

To resolve that question, the investigators assembled a multi-pronged evidence base that is unusually comprehensive for a single study. They mined public transcriptomic datasets from The Cancer Genome Atlas and the Gene Expression Omnibus, validated their findings in independent clinical tissue specimens obtained under ethics approval from Harbin Medical University Cancer Hospital, and then moved into functional laboratory work, including cell culture assays and an in vivo xenograft mouse model. The convergent message across these platforms was striking: DHCR24 was significantly upregulated in endometrial carcinoma compared with normal endometrial tissue, and elevated expression tracked tightly with advanced FIGO stage, high tumor grade, and poor patient survival.

Correlation alone does not establish causation, so the team next asked whether DHCR24 actively drives malignant behavior or merely rides along with it. In vitro, silencing the DHCR24 gene suppressed the proliferation, migration, and invasive capacity of endometrial cancer cells, while overexpressing the enzyme produced the opposite effect, sharpening the cells’ motility and growth. The xenograft experiments extended the story into living animals: tumors with diminished DHCR24 expression grew more slowly than their enzyme-rich counterparts. Together, these results position DHCR24 not as a passive bystander but as a functional contributor to tumor progression.

The most intriguing dimension of the study, however, lies in its exploration of how DHCR24 might exert these effects at the molecular level. Bioinformatic analyses of genes co-expressed with DHCR24 revealed enrichments in several pathways long associated with cancer aggressiveness: cholesterol metabolism itself, PI3K-Akt signaling, PPAR signaling, extracellular matrix-receptor interactions, cell cycle regulation, and, notably, cellular senescence-related pathways. This last finding is particularly provocative. Cellular senescence, the state of stable growth arrest that cells enter under stress, is a double-edged sword in oncology. On one hand, it acts as a tumor-suppressive barrier that halts damaged cells before they can divide. On the other, senescent cells that persist within tumors can secrete inflammatory and growth-promoting factors, collectively known as the senescence-associated secretory phenotype, which can nourish tumor growth, suppress immunity, and remodel tissue architecture.

To probe the senescence connection experimentally, the researchers measured the canonical molecular gatekeepers of the senescence program. When DHCR24 was knocked down in endometrial cancer cells, levels of p53, p21, and p16 rose, and staining for senescence-associated beta-galactosidase, a classic enzymatic marker of senescent cells, intensified. Conversely, when the enzyme was overexpressed, these senescence markers were dampened. The reciprocal Co-immunoprecipitation assays added a tantalizing biochemical clue: they suggested a physical association between DHCR24 and p53, the master guardian of the genome whose pathways are disabled in the vast majority of human cancers. The authors are careful to frame this as a potential association rather than a proven mechanism, but the implication is that DHCR24 may help tumor cells evade or escape p53-p21-p16-mediated senescence-like arrest, thereby sustaining uncontrolled proliferation.

The study also ventured into the immunological frontier. Exploratory immunoinformatics analyses suggested that DHCR24 expression may be associated with immune-related features in endometrial carcinoma, hinting that the enzyme could influence the tumor microenvironment. This line of inquiry is timely. Cholesterol metabolism has emerged as a key regulator of anti-tumor immunity, shaping everything from T cell membrane fluidity to immune checkpoint signaling, and recent work has shown that cellular senescence itself can be immunogenic, capable of provoking antitumor immune responses. If DHCR24 sits at the intersection of sterol metabolism, senescence regulation, and immune modulation, it could represent a nexus through which metabolic rewiring and immune evasion are coordinated in gynecological malignancy.

Context from earlier research gives the new findings added weight. A 2017 study had already shown that insulin-induced DHCR24 aggravates invasion and progesterone resistance in endometrial carcinoma, forging an early link between obesity-related hyperinsulinemia, cholesterol synthesis, and endometrial tumor aggression. Other groups reported that an anticancer peptide could suppress endometrial cancer growth by inhibiting DHCR24 through AKT-mediated signaling, and that DHCR24 insufficiency in vascular endothelial cells promotes senescence and endothelial dysfunction, underscoring the enzyme’s dual and context-dependent role in aging biology. The current study consolidates these threads within endometrial cancer specifically, adding prognostic validation across clinical cohorts and direct functional evidence from genetically manipulated cells and animal models.

For patients and clinicians, the near-term significance lies in prognostic stratification. Endometrial cancer currently lacks a rich arsenal of molecular markers to guide risk assessment beyond stage, grade, and established molecular classifications, and the identification of an easily measurable metabolic enzyme associated with stage, grade, and survival offers a potential addition to the clinical toolkit. For drug developers, the findings suggest that targeting DHCR24 or its downstream pathways, including PI3K-Akt and senescence regulators, could conceivably yield new therapeutic avenues, particularly for advanced and recurrent disease where options remain limited. The authors themselves, however, strike a deliberately cautious tone. They emphasize that further mechanistic and immunological validation is required before DHCR24’s therapeutic potential can be established, noting that the immunoinformatics findings remain exploratory and that the p53 association, while suggestive, does not yet amount to a defined biochemical mechanism.

What the study delivers, in the end, is a compelling reframe: an enzyme whose name appears on cholesterol biosynthesis charts is now a legitimate suspect in the progression of one of the fastest-growing cancers in women. As incidence rates continue their upward climb among younger and obese populations, understanding how metabolic enzymes like DHCR24 subvert ancient cellular safeguards such as senescence may prove essential to turning the tide. The Harbin Medical University team’s work, grounded in human datasets, clinical specimens, cell biology, and animal models, provides the foundational evidence base on which such understanding, and potentially future interventions, can be built.

Subject of Research: The role of the cholesterol biosynthesis enzyme DHCR24 in endometrial carcinoma progression and cellular senescence regulation

Article Title: DHCR24 promotes endometrial carcinoma progression and is associated with cellular senescence regulation

Article References: Li, F., Wang, Y., Wang, C., Osipova, A., Wang, H., Hu, J., Liu, Y., & Chen, X. (2026). DHCR24 promotes endometrial carcinoma progression and is associated with cellular senescence regulation. Medical Oncology, 43(10), Article 284. https://doi.org/10.1007/s12032-026-03406-3

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03406-3

Keywords: endometrial carcinoma, DHCR24, cholesterol metabolism, cellular senescence, p53, p21, p16, PI3K-Akt signaling, tumor progression, prognostic biomarker, xenograft model, tumor microenvironment